Showing 1 - 6 results of 6 for search 'Ira M Jacobson', query time: 0.03s Refine Results
  1. 1
    Persistence of hepatitis C virus during and after otherwise clinically successful treatment of chronic hepatitis C with standard pegylated interferon α-2b and ribavirin therapy.

    Persistence of hepatitis C virus during and after otherwise clinically successful treatment of chronic hepatitis C with standard pegylated interferon α-2b and ribavirin therapy. by Annie Y Chen, Marija Zeremski, Ranjit Chauhan, Ira M Jacobson, Andrew H Talal, Tomasz I Michalak

    Published 2013-01-01
    Get full text
    Article
  2. 2
    Comparison of Non-Tumoral Portal Vein Thrombosis Management in Cirrhotic Patients: TIPS Versus Anticoagulation Versus No Treatment

    Comparison of Non-Tumoral Portal Vein Thrombosis Management in Cirrhotic Patients: TIPS Versus Anticoagulation Versus No Treatment by Chenyang Zhan, Vinay Prabhu, Stella K. Kang, Clayton Li, Yuli Zhu, Sooah Kim, Sonja Olsen, Ira M. Jacobson, Nabil N. Dagher, Brendan Carney, Ryan M. Hickey, Bedros Taslakian

    Published 2021-05-01
    Get full text
    Article
  3. 3
    Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir With or Without Ribavirin in Patients With Kidney Disease

    Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir With or Without Ribavirin in Patients With Kidney Disease by David E. Bernstein, Albert Tran, Paul Martin, Kris V. Kowdley, Marc Bourliere, Mark S. Sulkowski, Paul J. Pockros, Boris Renjifo, Deli Wang, Diana L. Shuster, Daniel E. Cohen, Ira M. Jacobson

    Published 2019-02-01
    Get full text
    Article
  4. 4
    Hepatitis C viral evolution in genotype 1 treatment-naïve and treatment-experienced patients receiving telaprevir-based therapy in clinical trials.

    Hepatitis C viral evolution in genotype 1 treatment-naïve and treatment-experienced patients receiving telaprevir-based therapy in clinical trials. by Tara L Kieffer, Sandra De Meyer, Doug J Bartels, James C Sullivan, Eileen Z Zhang, Ann Tigges, Inge Dierynck, Joan Spanks, Jennifer Dorrian, Min Jiang, Bambang Adiwijaya, Anne Ghys, Maria Beumont, Robert S Kauffman, Nathalie Adda, Ira M Jacobson, Kenneth E Sherman, Stefan Zeuzem, Ann D Kwong, Gaston Picchio

    Published 2012-01-01
    Get full text
    Article
  5. 5
    P16 SOF/VEL/VOX for 8 or 12 weeks results in high SVR12 rates: an integrated analysis of the POLARIS-1, POLARIS-2, POLARIS-3 AND POLARIS-4 studies

    P16 SOF/VEL/VOX for 8 or 12 weeks results in high SVR12 rates: an integrated analysis of the POLARIS-1, POLARIS-2, POLARIS-3 AND POLARIS-4 studies by Stuart K. Roberts, Curtis L. Cooper, Eric Lawitz, K. Rajender Reddy, Alex J. Thompson, Stefan Zeuzem, Ira M. Jacobson, Peter Ruane, Robert H. Hyland, Luisa M. Stamm, Lingling Han, Diana M. Brainard, Norbert Bräu, Tarik Asselah, Bernard E. Willems, Steven Flamm, Marc Bourlière, Graham R. Foster, Edward J. Gane, Michael Manns, Stuart C. Gordon, Kris Kowdley

    Published 2017-08-01
    Get full text
    Article
  6. 6
    Long-term open-label vebicorvir for chronic HBV infection: Safety and off-treatment responses

    Long-term open-label vebicorvir for chronic HBV infection: Safety and off-treatment responses by Man-Fung Yuen, Scott Fung, Xiaoli Ma, Tuan T. Nguyen, Tarek Hassanein, Hie-Won Hann, Magdy Elkhashab, Ronald G. Nahass, James S. Park, Ira M. Jacobson, Walid S. Ayoub, Steven-Huy Han, Edward J. Gane, Katie Zomorodi, Ran Yan, Julie Ma, Steven J. Knox, Luisa M. Stamm, Maurizio Bonacini, Frank Weilert, Alnoor Ramji, Michael Bennett, Natarajan Ravendhran, Sing Chan, Douglas T. Dieterich, Paul Yien Kwo, Eugene R. Schiff, Ho S. Bae, Jacob Lalezari, Kosh Agarwal, Mark S. Sulkowski

    Published 2024-04-01
    Get full text
    Article

Search Tools: